Want to see VVOS full AI Analyst Report?
Total Valuation
Vivos Therapeutics has a market cap or net worth of $3.29M. The enterprise value is $19.70.
Market Cap$3.29M
Enterprise Value$19.70
Share Statistics
Vivos Therapeutics has 20,118,023 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,118,023
Owned by Insiders7.97%
Owned by Institutions0.63%
Financial Efficiency
Vivos Therapeutics’s return on equity (ROE) is 14.25 and return on invested capital (ROIC) is -123.14%.
Return on Equity (ROE)14.25
Return on Assets (ROA)-0.84
Return on Invested Capital (ROIC)-123.14%
Return on Capital Employed (ROCE)-2.81
Revenue Per Employee65.09K
Profits Per Employee-79.22K
Employee Count268
Asset Turnover0.69
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vivos Therapeutics is ―. Vivos Therapeutics’s PEG ratio is 0.14.
PE Ratio―
PS Ratio1.20
PB Ratio-14.00
Price to Fair Value-14.00
Price to FCF-1.18
Price to Operating Cash Flow-0.17
PEG Ratio0.14
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 17.44M and earned -21.23M in profits. Earnings per share was -2.06.
Revenue17.44M
Gross Profit10.54M
Operating Income-19.89M
Pretax Income-21.23M
Net Income-21.23M
EBITDA-19.92M
Earnings Per Share (EPS)-2.06
Cash Flow
In the last 12 months, operating cash flow was -17.13M and capital expenditures -810.00K, giving a free cash flow of -17.92M billion.
Operating Cash Flow-17.13M
Free Cash Flow-17.92M
Free Cash Flow per Share-0.89
Dividends & Yields
Vivos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change-95.43%
50-Day Moving Average0.31
200-Day Moving Average1.06
Relative Strength Index (RSI)28.15
Average Volume (3m)23.37M
Important Dates
Vivos Therapeutics upcoming earnings date is Nov 18, 2026, After Close (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Vivos Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -318.19%
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.42
Net Debt to EBITDA-0.58
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vivos Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vivos Therapeutics EV to EBITDA ratio is -1.62, with an EV/FCF ratio of -1.84.
EV to Sales1.85
EV to EBITDA-1.62
EV to Free Cash Flow-1.84
EV to Operating Cash Flow-2.12
Balance Sheet
Vivos Therapeutics has $1.77M in cash and marketable securities with $12.14M in debt, giving a net cash position of -$10.37M billion.
Cash & Marketable Securities$1.77M
Total Debt$12.14M
Net Cash-$10.37M
Net Cash Per Share-$0.52
Tangible Book Value Per Share-$1.38
Margins
Gross margin is 59.72%, with operating margin of -114.05%, and net profit margin of -121.71%.
Gross Margin59.72%
Operating Margin-114.05%
Pretax Margin-121.71%
Net Profit Margin-121.71%
EBITDA Margin-114.21%
EBIT Margin-121.71%
Analyst Forecast
The average price target for Vivos Therapeutics is $0.75, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.75
Price Target Upside240.91% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast45.21%
EPS Growth Forecast-10.29%